Dexrazoxane Cuts Bleeding in Severe Heart Attack Patients, Trial Finds

A drug already approved for cancer patients has shown it can reduce the worst complication of a severe heart attack, according to results presented at the European Society of Cardiology's annual congress in Munich on Aug 31. Newswise reported on Aug 31 that the Phase 2 SHIELD-MI trial, led by researchers at Indiana University School of Medicine, found that dexrazoxane reduced intramyocardial hemorrhage by 68% and infarct size by 34% in patients with ST-elevation myocardial infarction, the most serious type of heart attack. The results were published simultaneously in the European Heart Journal, and they represent the first trial to show a therapy can meaningfully reduce the bleeding into the heart muscle that complicates many of these cases.

The finding matters because intramyocardial hemorrhage, bleeding within the damaged heart muscle, is one of the hardest problems in modern cardiology. Reperfusion therapy, the procedure that restores blood flow to a blocked artery, saves lives, but it also can damage the muscle it is meant to save, and hemorrhage inside the infarct zone is associated with worse outcomes, larger infarcts and a higher risk of heart failure. If a drug that is already on the market, and already known to be tolerated by cancer patients, can reduce that bleeding, it could change the standard of care for a common and serious emergency.

Key Facts

Newswise reported on Aug 31 that the SHIELD-MI trial enrolled 123 patients with ST-elevation myocardial infarction, with the final analytic cohort consisting of 50 matched patients, 25 treated with dexrazoxane and 25 with placebo. The treatment regimen involved four doses of dexrazoxane: one before the percutaneous coronary intervention, the stent procedure that opens the blocked artery, and additional doses at 4, 8 and 12 hours afterward. The trial was presented at ESC Congress 2026 in Munich on Aug 31 by Keyur Vora of Indiana University School of Medicine, and published simultaneously in the European Heart Journal.

The results are the headline. The study found a 68% reduction in intramyocardial hemorrhage burden in patients treated with dexrazoxane compared with placebo, and a 34% reduction in infarct size. The treated patients also had a higher left ventricular ejection fraction, a measure of the heart's pumping function, which is a sign that the reduced bleeding translated into better preserved heart function. Newswise reported that the researchers described the effect as consistent across the study population, and that the drug was generally well tolerated in the trial.

Indiana University School of Medicine reported on Aug 31, in an announcement carried by Newswise, the underlying numbers that give the finding its statistical weight. Hemorrhage volume measured by cardiac magnetic resonance imaging was 2.0% of the ventricle in the dexrazoxane group versus 6.3% in the placebo group, a difference significant at P equals 0.004, and the rate of hemorrhagic myocardial infarction was 24% in treated patients versus 64% in the placebo group, significant at P equals 0.010. Left ventricular ejection fraction was 39.8% in the treated group versus 34.7% in the placebo group, and infarct volume was 29.1% versus 43.8%, with P values of 0.048 and 0.002 respectively. The European Society of Cardiology presented the findings on Aug 31 at ESC Congress 2026 in Munich, and the European Heart Journal published the study the same day. The trial, registered under NCT07502521, gave dexrazoxane at 250 milligrams per dose as a fixed four-dose regimen, and the investigators noted that intramyocardial hemorrhage affects about 40% of treated STEMI patients and is associated with a six-fold greater risk of major adverse cardiovascular events, including heart failure and death.

The scientific context gives the result its significance. Dexrazoxane is an FDA-approved oncology drug, used to prevent heart damage caused by certain chemotherapy agents, and it works by chelating iron, which reduces the free radical damage that follows reperfusion. The same mechanism is thought to be relevant in heart attacks, where iron released from damaged tissue contributes to the injury that occurs when blood flow is restored. The trial is the first to show that targeting that pathway can reduce the specific complication of hemorrhage in STEMI patients, and it sets up a larger Phase 3 trial to confirm the finding. Because the drug is already approved and its safety profile is established, the step from these results to a larger study is faster than it would be for a new molecule, which is one of the reasons the investigators chose it.

Analysis

What this really means is that the field of cardiology may have found a way to address one of the persistent failures of modern heart attack treatment: the damage that happens when you reopen the artery. Reperfusion is a double-edged sword. Opening the blocked vessel saves the muscle, but the rush of oxygenated blood into damaged tissue triggers a cascade of injury, and hemorrhage within the infarct is the most visible and most dangerous form of that injury. The SHIELD-MI results are significant because they show that a drug aimed at that specific mechanism, iron-driven oxidative damage, can reduce the bleeding by more than two-thirds, which is a large effect for a first trial in this setting.

The bigger picture here is about the strategy of repurposing drugs. Dexrazoxane is not a new molecule; it is an established oncology drug with a known safety profile, which means the path to approval in a new indication is shorter and cheaper than for a novel compound. That is a meaningful advantage in a field where the costs of developing new cardiovascular drugs are enormous and where many promising molecules have failed in late-stage trials. If dexrazoxane is confirmed in a Phase 3 trial, it could reach patients faster than a newly developed drug could, because the safety data already exist, and the manufacturing and supply chains already operate.

The results deserve careful interpretation. A 68% reduction in hemorrhage burden is a striking number, but the trial is small, with a final cohort of 50 matched patients, and the primary comparison is between 25 patients on each arm. Small trials can produce large apparent effects that do not reproduce in larger populations, which is why the investigators explicitly framed the results as the basis for a Phase 3 trial rather than a practice-changing finding. The ejection fraction improvement is encouraging, because it links the reduced bleeding to preserved heart function, but it is a secondary measure, and the difference, while positive, needs to be confirmed in a larger population. The honest assessment is that the mechanism, the pathway and the signal all look right, and the next trial will determine whether the promise holds. Until then, the responsible reading is cautious optimism: an effect this size in a small cohort demands replication before it changes how STEMI patients are treated.

Why It Matters

For patients who suffer severe heart attacks, the results point toward a possible treatment that could reduce the bleeding and the permanent heart damage that complicate recovery, and toward a future in which the damage from reperfusion is actively prevented rather than merely monitored. For cardiologists, the trial offers a new tool in the management of STEMI, the most serious and time-critical form of heart attack, and it adds hemorrhage reduction to the goals of reperfusion therapy. For the drug development community, the trial is a strong example of the repurposing strategy, showing that a drug with a known safety profile can be tested efficiently in a new disease. And for the broader field, the finding connects the biology of iron and oxidative stress, long studied in cardiology, to a specific clinical outcome, which is the kind of mechanistic progress that builds the case for the larger trial to come.

Next Up

In the coming months, watch for the announcement of the Phase 3 trial design, which will test dexrazoxane in a much larger population of STEMI patients and determine whether the 68% hemorrhage reduction and 34% infarct size reduction hold at scale. The longer-term questions are whether the drug reaches the emergency room as part of the standard treatment pathway, and whether the iron-chelation mechanism it targets proves to be a general strategy for reducing reperfusion injury across other ischemic conditions. For anyone following cardiology, the near-term takeaway is that the first trial to show a therapy can reduce bleeding inside the heart muscle reported results that were large, mechanistically coherent and published in a leading journal, and the Phase 3 trial that follows will be one of the most closely watched in the field.